# ğŸ“… Daily Report - 2026-01-27

> ä»Šæ—¥ç­›é€‰å‡º **35** æ¡å†…å®¹ï¼Œæ¥è‡ª **2** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
Smyd5ä»‹å¯¼IL-4è¡¨è§‚é—ä¼ è°ƒæ§å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œé©±åŠ¨Tç»†èƒååŒæŠ—è‚¿ç˜¤ï¼› hemeè°ƒæ§CD8+ Tç»†èƒè¡°ç«­çš„è½¬å½•æ´»æ€§ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
* è‚¿ç˜¤å…ç–«ï¼šè§£æè‚¿ç˜¤å¾®ç¯å¢ƒã€å·¨å™¬ç»†èƒä¸Tç»†èƒçš„ç›¸äº’ä½œç”¨ï¼Œä»¥åŠè¡¨è§‚é—ä¼ è°ƒæ§æœºåˆ¶ã€‚
* ç–¾ç—…æœºåˆ¶ï¼šç ”ç©¶å°è‚ å’Œç»“è‚ åŒ–ç”Ÿæ€§Panethç»†èƒã€é¼»æ—çª¦é³çŠ¶ç»†èƒç™Œã€å¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ã€é˜¿å°”èŒ¨æµ·é»˜ç—…å°é¼ æ¨¡å‹ã€è´¥è¡€ç—‡æ€§å¿ƒè‚Œç—…ç­‰ç–¾ç—…çš„åˆ†å­åŸºç¡€ã€‚
* ç»†èƒç”Ÿç‰©å­¦ï¼šæ¢ç´¢å¤–æ³Œä½“åŠ¨åŠ›å­¦ã€RORÎ³t+å…ˆå¤©å…ç–«ç»†èƒåˆ†åŒ–ã€CD8+ Tç»†èƒå¹²æ€§ç»´æŒã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
* å¤šç»„å­¦æ•´åˆåˆ†æï¼ˆMulti-omic profilingï¼‰æ­ç¤ºå¤æ‚ç–¾ç—…çš„åˆ†å­å›¾è°±ã€‚
* ç©ºé—´è½¬å½•ç»„å­¦ï¼ˆSpatial transcriptomicsï¼‰å’Œå•ç»†èƒæµ‹åºï¼ˆscRNA-seqï¼‰æä¾›é«˜åˆ†è¾¨ç‡çš„ç»†èƒå’Œç»„ç»‡ä¿¡æ¯ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
æ­ç¤ºäº†è‚ é“æ…¢æ€§ç‚ç—‡å‘å±•ä¸ºç»“ç›´è‚ ç™Œçš„æ½œåœ¨å…ç–«æœºåˆ¶ï¼Œä»¥åŠé˜¿å°”èŒ¨æµ·é»˜ç—…é€šè¿‡åˆ†å­å¼€å…³è¯±å¯¼ç¥ç»å…ƒâ€œè‡ªæˆ‘å‰ªæâ€ä»¥è‡´è®°å¿†ä¸§å¤±çš„æœºåˆ¶ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- è‚ é“ç‚ç—‡ä¸ç»“ç›´è‚ ç™Œå‘ç—…æœºåˆ¶
- é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³çš„ç¥ç»å…ƒè¿æ¥æŸä¼¤ä¸è®°å¿†ä¸¢å¤±

**æŠ€æœ¯äº®ç‚¹**ï¼š
- å‘ç°è‚ é“å…ç–«é“¾å¼ååº”åœ¨ç‚ç—‡æ€§è‚ ç—…å‘ç»“ç›´è‚ ç™Œè½¬åŒ–ä¸­çš„ä½œç”¨ã€‚
- è¯†åˆ«å‡ºæ·€ç²‰æ ·Î²å’Œç‚ç—‡ä¿¡å·æ±‡èšçš„åŒä¸€åˆ†å­å¼€å…³ï¼Œå¯¼è‡´ç¥ç»å…ƒå‰ªæã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (33æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE315361 Smyd5 ä»‹å¯¼ IL-4 è¡¨è§‚é—ä¼ æ§åˆ¶å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œä»è€Œé©±åŠ¨ååŒ T ç»†èƒä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶ [RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€T cellã€macrophageã€antigenã€RNA-seqã€epigenetic
- ğŸ“ **æè¿°**ï¼šContributors : Buyun Dang ; Yuling Hong ; Qingxiang Gao ; Shih-Chin ChengSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusIL-4 is classically associated with â€œM2â€ macrophages considered tumor-immunosuppressive, yet marker-based labels poorly reflect macrophage function in tumors. Reports of a non-canonical, IL-4â€“imprinted macrophage state (M2inf) with trained-immunity features prompted us to test whether such imprinting contributes to antitumor immunity in vivo. Here we show that, in B16F10 melanoma, IL-4 programs macrophages through the lysine methyltransferase Smyd5 to deposit promoter-proximal H3K36me3, increase MHC class II, and potentiate T cell activation. Myeloid Il4ra deletion increased tumor burden and reduced MHC class II and intratumoral T cell activation, whereas co-transfer of IL-4â€“primed macrophages suppressed tumors and expanded activated CD4 and CD8 T cells. Antitumor benefit required adaptive lymphocytes and macrophage-intrinsic MHC class II, as Rag1 deficiency or macrophage Rfx5 deletion abrogated tumor suppression. These findings identify a non-canonical, IL-4â€“imprinted macrophage program that enables antigen presentation and cooperative T cell immunity in this tumor context.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315361)

**2.** â­ **GSE315255 Smyd5 ä»‹å¯¼ IL-4 è¡¨è§‚é—ä¼ æ§åˆ¶å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œä»è€Œé©±åŠ¨ååŒ T ç»†èƒä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶ [scRNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€T cellã€macrophageã€antigenã€scRNAã€epigenetic
- ğŸ“ **æè¿°**ï¼šContributors : Buyun Dang ; Yuling Hong ; Qingxiang Gao ; Shih-Chin ChengSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusIL-4 is classically associated with â€œM2â€ macrophages considered tumor-immunosuppressive, yet marker-based labels poorly reflect macrophage function in tumors. Reports of a non-canonical, IL-4â€“imprinted macrophage state (M2inf) with trained-immunity features prompted us to test whether such imprinting contributes to antitumor immunity in vivo. Here we show that, in B16F10 melanoma, IL-4 programs macrophages through the lysine methyltransferase Smyd5 to deposit promoter-proximal H3K36me3, increase MHC class II, and potentiate T cell activation. Myeloid Il4ra deletion increased tumor burden and reduced MHC class II and intratumoral T cell activation, whereas co-transfer of IL-4â€“primed macrophages suppressed tumors and expanded activated CD4 and CD8 T cells. Antitumor benefit required adaptive lymphocytes and macrophage-intrinsic MHC class II, as Rag1 deficiency or macrophage Rfx5 deletion abrogated tumor suppression. These findings identify a non-canonical, IL-4â€“imprinted macrophage program that enables antigen presentation and cooperative T cell immunity in this tumor context.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315255)

**3.** â­ **GSE315253 Smyd5 ä»‹å¯¼ IL-4 è¡¨è§‚é—ä¼ æ§åˆ¶å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œä»è€Œé©±åŠ¨ååŒ T ç»†èƒä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶ [ATAC-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€T cellã€macrophageã€antigenã€ATAC-seqã€epigenetic
- ğŸ“ **æè¿°**ï¼šContributors : Buyun Dang ; Yuling Hong ; Qingxiang Gao ; Shih-Chin ChengSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusIL-4 is classically associated with â€œM2â€ macrophages considered tumor-immunosuppressive, yet marker-based labels poorly reflect macrophage function in tumors. Reports of a non-canonical, IL-4â€“imprinted macrophage state (M2inf) with trained-immunity features prompted us to test whether such imprinting contributes to antitumor immunity in vivo. Here we show that, in B16F10 melanoma, IL-4 programs macrophages through the lysine methyltransferase Smyd5 to deposit promoter-proximal H3K36me3, increase MHC class II, and potentiate T cell activation. Myeloid Il4ra deletion increased tumor burden and reduced MHC class II and intratumoral T cell activation, whereas co-transfer of IL-4â€“primed macrophages suppressed tumors and expanded activated CD4 and CD8 T cells. Antitumor benefit required adaptive lymphocytes and macrophage-intrinsic MHC class II, as Rag1 deficiency or macrophage Rfx5 deletion abrogated tumor suppression. These findings identify a non-canonical, IL-4â€“imprinted macrophage program that enables antigen presentation and cooperative T cell immunity in this tumor context.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315253)

**4.** â­ **GSE315363 Smyd5 ä»‹å¯¼ IL-4 è¡¨è§‚é—ä¼ æ§åˆ¶å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œä»è€Œé©±åŠ¨ååŒ T ç»†èƒä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶ [Crispr ç­›é€‰]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€T cellã€macrophageã€antigenã€epigenetic
- ğŸ“ **æè¿°**ï¼šContributors : Buyun Dang ; Yuling Hong ; Qingxiang Gao ; Shih-Chin ChengSeries Type : OtherOrganism : Mus musculusIL-4 is classically associated with â€œM2â€ macrophages considered tumor-immunosuppressive, yet marker-based labels poorly reflect macrophage function in tumors. Reports of a non-canonical, IL-4â€“imprinted macrophage state (M2inf) with trained-immunity features prompted us to test whether such imprinting contributes to antitumor immunity in vivo. Here we show that, in B16F10 melanoma, IL-4 programs macrophages through the lysine methyltransferase Smyd5 to deposit promoter-proximal H3K36me3, increase MHC class II, and potentiate T cell activation. Myeloid Il4ra deletion increased tumor burden and reduced MHC class II and intratumoral T cell activation, whereas co-transfer of IL-4â€“primed macrophages suppressed tumors and expanded activated CD4 and CD8 T cells. Antitumor benefit required adaptive lymphocytes and macrophage-intrinsic MHC class II, as Rag1 deficiency or macrophage Rfx5 deletion abrogated tumor suppression. These findings identify a non-canonical, IL-4â€“imprinted macrophage program that enables antigen presentation and cooperative T cell immunity in this tumor context.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315363)

**5.** â­ **GSE306374 å°è‚ å’Œç»“è‚ åŒ–ç”Ÿæ½˜æ°ç»†èƒçš„ç©ºé—´è½¬å½•ç»„å­¦é—ä¼ è°±**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šspatialã€spatial transcriptomicsã€transcriptomicsã€regex:intestin(e|al)
- ğŸ“ **æè¿°**ï¼šContributors : Tomohiro Muto ; Go ItoSeries Type : OtherOrganism : Homo sapiensMetaplasia is an epithelial alteration that appears in chronic inflammatory diseases. In ulcerative colitis, Paneth cell metaplasia (PCM) is a well-recognized feature, but its role in the inflamed epithelium remains unclear. Using spatial transcriptomics, we characterized the gene expression profile of PCM, elucidated its regulatory mechanisms, and clarified its functional role in the inflamed colonic epithelium.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306374)

**6.** â­ **GSE298564 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [RPMI 2650 æ‰¹é‡ ATAC-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€carcinomaã€tumor microenvironmentã€ATAC-seq
- ğŸ“ **æè¿°**ï¼šContributors : Chaelin You ; Junho Noh ; Jiheui Kim ; Kyuho KangSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensSinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298564)

**7.** â­ **GSE298563 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [RPMI2650 æ‰¹é‡ RNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€carcinomaã€tumor microenvironmentã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Chaelin You ; Junho Noh ; Jiheui Kim ; Kyuho KangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298563)

**8.** â­ **GSE278145 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [æ‰¹é‡ RNA æµ‹åº]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€carcinomaã€tumor microenvironmentã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Chaelin You ; Jihwan Park ; Keunsoo Kang ; Jaewoo Park ; Jungyeon Jang ; Myeongsang Yu ; Yoosam Chung ; Jiheui Kim ; Kyuho KangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278145)

**9.** â­ **GSE278138 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ[DNAç”²åŸºåŒ–]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€carcinomaã€tumor microenvironmentã€methylation
- ğŸ“ **æè¿°**ï¼šContributors : Chaelin You ; Jihwan Park ; Keunsoo Kang ; Jaewoo Park ; Jungyeon Jang ; Myeongsang Yu ; Yoosam Chung ; Jiheui Kim ; Kyuho KangSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensSinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278138)

**10.** â­ **GSE288091 å¯¹ç» SOT101 å¤„ç†çš„ TC-1 å’Œ TRAMP-C å°é¼ çš„è‚¿ç˜¤ã€è„¾è„ã€æ·‹å·´ç»“ä¸­çš„ RNA æ ·æœ¬è¿›è¡Œ Nanostring åˆ†æ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€lymphã€regex:lymph(o|atic)?
- ğŸ“ **æè¿°**ï¼šContributor : Lenka P JelinkovaSeries Type : OtherOrganism : Mus musculusNanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor Î²Î³ superagonist that stimulates natural killer (NK) and CD8+ T cells, thereby promoting an innate and adaptive anti-tumor inflammatory microenvironment in mouse tumor models either in monotherapy or combined with an anti-programmed cell death protein 1 (PD-1) antibody. In cynomolgus monkeys, a clinical schedule was identified, which translated into the design of a phase 1/1b clinical trial, AURELIO-03 (NCT04234113). In 51 patients with advanced/metastatic solid tumors, nanril increased the proportions of CD8+ T cells and NK cells in peripheral blood and tumors. It had a favorable safety profile when administered subcutaneously on days 1, 2, 8 and 9 of each 21-day cycle as monotherapy (0.25-15 Î¼g/kg) or combined (1.5-12 Î¼g/kg) with the anti-PD-1 pembrolizumab (200 mg). The most frequent treatment-emergent adverse events were pyrexia, injection site reactions and chills. Furthermore, early clinical efficacy was observed, including in immune checkpoint blockade-resistant/refractory patients.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288091)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 23 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (2æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰

**1.** â­ **ä¸ºä»€ä¹ˆæ…¢æ€§è‚ é“ç‚ç—‡ä¼šå‘å±•æˆç»“è‚ ç™Œ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€inflammationã€gutã€regex:gut(-?microbiome)?
- ğŸ“ **æè¿°**ï¼šA newly uncovered immune chain reaction in the gut may explain why people with inflammatory bowel disease face a much higher risk of colorectal cancer. Researchers found that a powerful inflammatory signal flips on specialized gut immune cells, which then call in waves of white blood cells from the bone marrow and rewire them in ways that help tumors grow. This process appears to damage DNA in the gut lining and create a tumor-friendly environment.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/01/260125083401.htm)

**2.** **é˜¿å°”èŒ¨æµ·é»˜ç—…å¯èƒ½ä¼šæ¬ºéª—å¤§è„‘ï¼Œä½¿å…¶æŠ¹å»è‡ªèº«çš„è®°å¿†ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šAlzheimer
- ğŸ“ **æè¿°**ï¼šAlzheimerâ€™s may destroy memory by flipping a single molecular switch that tells neurons to prune their own connections. Researchers found that both amyloid beta and inflammation converge on the same receptor, triggering synapse loss. Surprisingly, neurons arenâ€™t passive victimsâ€”they actively respond to these signals. Targeting this receptor could offer a new way to protect memory beyond current amyloid-focused drugs.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/01/260125083413.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| tumor | 11 |
| RNA-seq | 7 |
| T cell | 6 |
| carcinoma | 6 |
| macrophage | 6 |
| tumor microenvironment | 6 |
| ATAC-seq | 4 |
| antigen | 4 |
| epigenetic | 4 |
| immune | 3 |
| cancer | 3 |
| sequencing | 2 |
| Alzheimer | 2 |
| spatial | 2 |
| transcriptomics | 2 |
| single-cell | 1 |
| lymph | 1 |
| regex:lymph(o|atic)? | 1 |
| Visium | 1 |
| metabolic | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (23æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE280209 VAMP7ä¾èµ–çš„å†…è´¨ç½‘å’Œçº¿ç²’ä½“è›‹ç™½çš„æ™šæœŸå†…ä½“åˆ†æ³Œå½±å“è‚¿ç˜¤å¾®ç¯å¢ƒå’Œå·¨å™¬ç»†èƒçš„å‚ä¸](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280209)
- [GSE277797 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [snMultiome-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277797)
- [GSE312103 RNA-seq æ­ç¤ºå¤–æºæ€§è¡€çº¢ç´ æ²»ç–—åŠ é€Ÿ CD8+ T ç»†èƒè€—ç«­](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312103)
- [GSE312102 ATAC-seq æ­ç¤ºè¡€çº¢ç´ è°ƒèŠ‚é©±åŠ¨ CD8âº T ç»†èƒè€—ç«­çš„è½¬å½•å› å­çš„è½¬å½•æ´»æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312102)
- [GSE312100 å•ç»†èƒ RNA æµ‹åºæ­ç¤ºï¼Œå…·æœ‰éæ´»æ€§è¡€çº¢ç´ ç»“åˆä½ç‚¹çš„ Bach2 ç»´æŒ CD8+ T ç»†èƒçš„å¹²æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312100)
- [GSE263465 çŒªèƒŒæ ¹ç¥ç»èŠ‚ç¥ç»å…ƒçš„ç©ºé—´è½¬å½•ç»„åˆ†å­ç‰¹å¾[Visium]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263465)
- [GSE317235 SAGA/ATACå¤åˆç‰©ç»´æŒå¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ä¸­å¼‚å¸¸çš„æŸ“è‰²è´¨è°ƒæ§å’Œä»£è°¢ç¨‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317235)
- [GSE311597 åˆ†å±‚ Rorc(Î³t) é¡ºå¼è°ƒæ§çº§è”åè°ƒ RORÎ³tâº å…ˆå¤©å…ç–«ç»†èƒçš„åˆ†åŒ– [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311597)
- [GSE311595 åˆ†å±‚ Rorc(Î³t) é¡ºå¼è°ƒæ§çº§è”åè°ƒ RORÎ³tâº å…ˆå¤©å…ç–«ç»†èƒçš„åˆ†åŒ– [ATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311595)
- [GSE302249 è‚ºç™Œä¸­è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒçŠ¶æ€ä¸éä¿å®ˆæ€§lncRNAçš„å…³è”](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302249)
- [GSE304308 é˜¿å°”èŒ¨æµ·é»˜ç—…å°é¼ çš„è„‘è„‚è´¨è°±å’Œå°‘çªèƒ¶è´¨ç»†èƒåŸºå› è¡¨è¾¾å¯¹é«˜è„‚é¥®é£Ÿçš„ååº”ä¸ä¸€è‡´ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304308)
- [GSE317178 çº³ç±³è§å…‰ç´ é…¶-CD63æ ‡è®°æ­ç¤ºäº†å°é¼ å¯¼ç®¡åŸä½ç™Œå¯¼ç®¡å†…æ¨¡å‹ä¸­ç»†èƒå¤–å›Šæ³¡çš„åŠ¨åŠ›å­¦](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317178)
- [GSE317110 åˆ©ç”¨16S rRNAæµ‹åºå¯¹å¤§é¼ ç²ªä¾¿æ ·æœ¬ä¸­çš„å¯¹ç…§ç»„ã€æ”¾å°„æ€§è‚ ç‚æ¨¡å‹ç»„å’Œæ²»ç–—ç»„è¿›è¡Œå¾®ç”Ÿç‰©ç»„åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317110)
- [GSE317084 å¼‚æ¶å”‘è‹¯å’ŒPEP3è”åˆå¤„ç†åæ‹Ÿå—èŠ¥å¹¼è‹—çš„è½¬å½•ç»„åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317084)
- [GSE316845 RNA-Seqç»“æœï¼Œæ¥è‡ªå‡æ‰‹æœ¯ç»„ã€è„“æ¯’ç—‡è¯±å¯¼å¿ƒè‚Œç—…ç»„å’ŒAAV-GATA4ç»„å°é¼ çš„å¿ƒè„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316845)
- [GSE315074 äººç±»å•æ ¸ç»†èƒæ¥æºçš„å·¨å™¬ç»†èƒä¸­è¿‡è¡¨è¾¾TRIM21ã€NFATc3æˆ–ASK1çš„å·®å¼‚è¡¨è¾¾åŸºå› ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315074)
- [GSE313641 RNA-seq åˆ†æéª¨è†œè›‹ç™½åˆºæ¿€çš„äººé¼»ä¸Šçš®ç»†èƒ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313641)
- [GSE311856 å¯¹ MHC I ç±»åˆ†å­ä¼´ä¾£ tapasin çš„ä¸€ç§å˜ä½“ tapasin è¿›è¡Œæ·±åº¦çªå˜æ‰«æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311856)
- [GSE311596 åˆ†å±‚ Rorc(Î³t) é¡ºå¼è°ƒæ§çº§è”åè°ƒ RORÎ³tâº å…ˆå¤©å…ç–«ç»†èƒçš„åˆ†åŒ– [ChIL-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311596)
- [GSE309067 ç»†èƒç‰¹å¼‚æ€§è½¬å½•ç»„å­¦å’ŒåŸºå› æ²‰é»˜æ­ç¤ºæ°´é€šé“è›‹ç™½åœ¨ç¦¾æœ¬ç§‘æ¤ç‰©æ°”å­”è¿åŠ¨ä¸­çš„åŠŸèƒ½](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309067)
- [GSE293843 è¯ç‰©æˆ–åŸºå›  PIKFYVE æŠ‘åˆ¶å¯¹ GEP-NET çš„å½±å“ [RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293843)
- [GSE254518 DNAJB1è¡¨è¾¾é™ä½å¯¼è‡´é»‘è´¨è¡°è€ï¼šæ¥è‡ªå•æ ¸RNAæµ‹åºçš„å¯ç¤º](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254518)
- [GSE223837 SOX6è¯±å¯¼çš„ç»†èƒè¡°è€ä¸è¡°è€ç»†èƒæ¸…é™¤ç–—æ³•çš„è”åˆåº”ç”¨å¯æé«˜å®«é¢ˆç™Œçš„åŒ–ç–—æ•æ„Ÿæ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223837)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-26 21:43*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*